SF-106(SF-106) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

眼部疾病

在研适应症-

非在研适应症

视网膜疾患

原研机构

Societá Industria Farmaceutica Italiana Spa (S.I.F.I.)

在研机构-

非在研机构

Societá Industria Farmaceutica Italiana Spa (S.I.F.I.)

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 SF-106 相关的临床结果

登录后查看更多信息

100 项与 SF-106 相关的转化医学

登录后查看更多信息

100 项与 SF-106 相关的专利（医药）

登录后查看更多信息

1

项与 SF-106 相关的文献（医药）

2024-06-14·Beneficial Microbes

Bacillus subtilis SF106 and Bacillus clausii SF174 spores reduce the inflammation and modulate the gut microbiota in a colitis model

Article

作者: Baccigalupi, L ; Ricca, E ; Vittoria, M ; Saggese, A ; Cutting, S M ; Horwell, E ; Bastoni, D

AbstractChronic intestinal inflammation is associated with strong alterations of the microbial composition of the gut. Probiotic treatments and microbiota-targeting approaches have been considered to reduce the inflammation, improve both gut barrier function as well as overall gastrointestinal health. Here, a murine model of experimental colitis was used to assess the beneficial health effects of Bacillus subtilis SF106 and Bacillus clausii (recently renamed Shouchella clausii) SF174, two spore-forming strains previously characterised in vitro as potential probiotics. Experimental colitis was induced in BALB/c mice by the oral administration of dextran sodium sulphate (DSS) and groups of animals treated with spores of either strain. Spores of both strains reduced the DSS-induced inflammation with spores of B. clausii SF174 more effective than B. subtilis SF106. Spores of both strains remodelled the mouse gut microbiota favouring the presence of beneficial microbes such as members of the Bacteroidetes and Akkermansia genera.

100 项与 SF-106 相关的药物交易

登录后查看更多信息